This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Concurrent Crushed; Cognex Cruises

NEW YORK ( TheStreet) -- Concurrent Computer (CCUR - Get Report) shares took a big hit on light volume late Monday after the Atlanta-based video delivery technology company swung back to a quarterly loss because of weak margins and a sequential decline in revenue.

After the closing bell, the company posted a loss of $1.2 million, or 14 cents a share, for its fiscal first quarter ended on Sept. 30 with revenue totaling $15.5 million. The performance was down on a sequential basis from its profit of $886,000, or 11 cents a share, on revenue of $18.1 million for its fourth quarter ended in June. The expectation of the single analyst covering the company was for earnings of 3 cents a share in the September period.

The stock was last quoted at $4.95, down 28.3%, according to, on slight afterhours volume of less than 8,000; although the issue's trailing three-month daily average churn is around 30,000. Based on a regular session close at $6.90, the shares were up almost 60% year-to-date, including a nearly 9% rally on Monday ahead of the report. The thinly traded stock hit a new 52-week high of $7.31 during Monday's session, so the market reaction to any disappointment in the numbers is likely to be dramatic.

"Margins [in the latest quarter] were impacted by costs associated with the ramp-up of MDAS [Media Data and Advertising Solutions] managed services solutions and introduction of a new video product in the quarter, as well as a cyclical change in the mix of products and services," said Dan Mondor, the company's president and CEO, in a statement.

Concurrent didn't provide a specific financial outlook in its statement but CEO Mondor said the company expects near-term results to "continue to be restrained by cautious customer spending patterns, as well as by ongoing investments we are making in the transformation of the company."

Moving higher in extended trades was Ironwood Pharmaceuticals (IRWD - Get Report), which was quoted up 12.6% at $11.90 on volume of a little less than 13,000. The company and partner Forest Laboratories (FRX) reported positive top-line clinical results of a second phase III trial of linaclotide, a proposed treatment for patients with irritable bowel syndrome with constipation.

A Forest Labs executive said in the press release announcing the positive results that the company expects to file new drug applications related to linaclotide for indications of treating both chronic constipation and irritable bowel syndrome with constipation in 2011.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FRX $99.00 -0.77%
CGNX $37.27 0.00%
CCUR $4.94 0.00%
IRWD $12.26 0.00%
AAPL $117.81 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs